StemSynergy Therapeutics, Inc.
"Innovative Stem Cell Research. Targeted Cancer Therapeutics."

Publications

  1. Li, B. et al. Pyrvinium attenuates Hedgehog signaling downstream of Smoothened. Cancer Research (2014).
  2. Li, B. et al. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PLoS One 9, 1-9 (2014).
  3. Barham, W. et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discovery 3, 1286-1301 (2013).
  4. Xu, W. et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One 8, 1-12 (2013).
  5. Thorne, C.A. et al. A biochemical screen for identification of small-molecule regulators of the Wnt pathway using Xenopus egg extracts. Journal of Biomolecular Screening 16, 995-1006 (2011).
  6. Thorne, C.A. et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1 alpha. Nature Chemical Biology 6, 829-836 (2010).

Scientific Team

SSTI has a multidisciplinary team of scientists.

Meet the Team

Leadership

Meet the Leadership behind StemSynergy Therapeutics, Inc.

Meet Leadership

Cancer Research

Targeting the developmental pathways that drive cancer.

Cancer Research